ki:e SB-C

The ki:elements speech biomarker for cognition

Check out our new validation results on remote speech biomarker for cognition (SB-C) in early Alzheimer’s disease
Tröger J, Baykara E, Zhao J, ter Huurne D, Possemis N, Mallick E, Schäfer S, Schwed L, Mina M, Linz N, Ramakers I, Ritchie C: Validation of the Remote Automated ki:e Speech Biomarker for Cognition in Mild Cognitive Impairment: Verification and Validation following DiME V3 Framework. Digit Biomark 2022;6:107-116. doi: 10.1159/000526471

ki:elements speech biomarker for cognition

Measuring cognition through a scalable speech biomarker

The ki:e SB-C is based on speech recordings from two gold standard cognitive tests (Semantic Verbal Fluency and Rey Auditory Verbal Learning task) that take 10-15 minutes to perform. More than 120 features are automatically extracted from the recordings and combined into a cognitive composite and three sub-scales measuring executive function, episodic memory, and processing speed.

It has applicability to the following disease areas:

  • Alzheimer’s disease
  • Parkinson’s disease
  • Schizophrenia
  • Multiple sclerosis
  • Mild Cognitive Impairment
It is available in the following languages: English, German, French, Dutch, Swedish, Spanish

A valid clinical measure

Compiling validation evidence in an evidence dossier

The SB-C has been validated in multiple studies to show relation to existing measures (i.e., MMSE, CDR), its test-retest reliability and its ability to detect clinically meaningful differences. The full validation evidence is compiled in an evidence dossier according to scientific standards (DIME, Walton 2020).

Correlation with the MMSE

Strong correlation of the ki:e SB-C biomarker with MMSE total score.

Discriminating between stages

Significant group differences between Dementia, MCI and HC.

SB-C in action

Measuring cognition in different applications in and around trials

SB-C can be used for multiple different applications in and around trials. It’s a valid measure to track cognition and can be used as a decentralized assessment tool. SB-C can also be used to screen participants for Mild cognitive impairment (MCI), e.g., as a pre-screener for trial recruitment.


ki:e SB-C

Use SB-C in your study!

Get in touch

We’re looking forward to working with you! SB-C is deployed via our Mili platform into clinical studies and trials. If you are interested in deploying it in your study, please reach out to us.

Academic groups wanting to use the technology can partner with us to receive reduced licensing costs.

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.